| Jun/78 – May/79 |
Clinical Investigation of Oral Candidiasis and Salivary Immunoglobulin; National Institute of Health, USA |
| Jun/79 – May/80 |
Clinical Aspects and Effects of Treatment on Host Parasite Interactions of Candida Albicans; NIH |
| Jun/81 – May/82 |
Oral Candidiasis: A Complication of Topical Steroid Therapy; Dean’s MRC Fund |
| Jun/81 – May/82 |
Hepatitis B in Canadian Dentists; Dean’s MRC Fund |
| Jun/81 – May/82 |
Effects of a Sialagogue (Sialor) on Saliva Flow and Saliva Composition in Humans; Dean’s MRC Fund |
| Jan/84 – 1987 |
A Prospective Double Blind Clinical Trial of Benzydamine Hydrochloride
(Tantum) in Prevention and Management of Oral Mucositis Associated with Radiation Therapy; Riker 3M Canada |
| Jan/85 – Jan/90 |
Clinical Study of the use of Chlorhexidine in Patients with Malignant Hematologic Disease; Ayerst Canada |
| Jan/85 – 1987 |
Extraction of Teeth and Complication of Osteonecrosis in Patients Treated with Radiation Therapy in the Maxilla and Mandible |
| 1986 – 1990 |
Topical Bleomycin in Management of Oral Leukoplakia; Bristol Meyers Co. |
| 1987 – 1994 |
The Modification of the Radiation Effect on Salivary Function by ASA in Patients with Nasopharyngeal Carcinoma; Vancouver Foundation |
| Sep/88 – 1993 |
Double Blind Study of the Use of Sucralfate in Prevention of Radiation Mucositis; Nordic |
| 1993 – 1994 |
A double-blind Comparison of Itraconazole Oral Solution and Fluconazole
Capsules for the Treatment of Oral Candidosis in AIDS patients. Phillips P,
Epstein J (investigators) Janssen Pharmaceutical |
| 1993 – 2001 |
EGF and Oral Mucositis in Patients receiving Bone Marrow Transplantation. Epstein JB (investigator), Parke-Davis Pharmaceutical Research |
| 1993 – 1997 |
A double-blind Crossover Trial of Oral Balance and Biotene Toothpaste
Versus Placebo in Patients with Xerostomia Following Radiation
Therapy. Epstein JB, Stevenson-Moore P, Le N (investigators). Laclede
Professional Products |
| 1994 – 1997 |
Benzydamine HCL in the Prophylactic Treatment of Postradiation Oral Mucositis. Epstein JB (investigator), Angelini Pharmaceuticals, Inc. |
| 1994 – 1998 |
Assessment of the Quality of Life and Oral Function in Cancer Patients |
| 1995 – 2000 |
Loss of heterozygosity in premalignant and malignant oral lesions |
| 1995 – 2000 |
Loss of heterozygosity in premalignant and malignant oral lesions Management of premalignant oral lesions
|
| 1995 – 2000 |
Assessment of toluidine blue rinse as an aid to clinical exam in the identification of recurrent or second primary cancers of the oral cavity and in biopsy site selection in patients with previous oral/oropharyngeal and other upper aerodigestive tract squamous cell carcinomas |
| 1995 – 2000 |
Assessment of toluidine blue rinse as an aid to clinical exam in the identification of recurrent or second primary cancers of the oral cavity and in biopsy site selection in patients with previous oral/oropharyngeal and other upper aerodigestive tract squamous cell carcinomas |
| 1996 – 1997 |
An open, multi-centre comparative study of the efficacy, safety and toleration of fluconazole oral suspension versus nystatin oral suspension in the treatment of oropharyngeal candidiasis in patients with malignancy |
| 1997 – 2001 |
Acyclovir versus valacyclovir in the prevention of mucocutaneous herpes simplex virus infections in immunocompromised hosts: a randomized, single-blind trial |
| 1997 – 2003 |
A randomized trial comparing fungizone oral suspension to nystatin oral suspension in prophylaxis or oropharyngeal candidiasis in bone marrow transplantation |
| 1997 – 2005 |
Quality of life and Oral Function in Cancer Patients |
| 1997 – 2005 |
Assessment of Bethanechol for treatment of hyposalivation in head and neck cancer patients |
| 2000 – 2002 |
A multinational, multicenter, double-blind, placebo-controlled, randomised, Phase III Clinical trial to determine the efficacy and safety of IB-367 rinse in reducing the severity of oral mucositis in patients receiving radiotherapy for head and neck malignancy (Intrabiotics Pharmaceuticals) |
| 2001 – 2002 |
Evaluation of Tolonium Chloride (Toluidine Blue) the detection of Locally Recurrent or New Primary Oral Cavity Cancers and Cancer In Situ (Zila Pharmaceuticals) |
| 2003 – 2006 |
A Phase II multicenter double blind placebo controlled parallel group dose ranging study of the effects of RK-0202 on oral mucositis in patients receiving radiation therapy for carcinoma of the oral cavity oropharynx, or nasopharynx. RxKinetix Inc. Louisville, CO |
| 2003 – 2004 |
A double blind randomized vehicle controlled study comparing the safety and efficacy of benzydamine hydrochloride 0.15% oral rinse including a separate open label standard of care arm in subjects with radiation induced mucositis. McNeil Pharmaceuticals, Ft Washington, Penn |
| 2003 – 2005 |
Longitudinal evaluation of mucositis patient reported outcomes among individuals undergoing radiation therapy with or without chemotherapy for head and neck cancer. Amgen Los Angeles, CA |
| 2003 – 2005 |
The use of oral speculoscopy with the adjunctive use of tolonium chloride vital staining. Vizilite Corp. Los Angeles CA |
| 2004 – |
A dose escalating pilot trial to determine the topical dose of morphine sulfate most effective in reducing the pain of radiation induced oral mucositis |
| 2005 – 2006 |
Evaluating the Cost of Care for Early and Late Stage Oropharyngeal Cancer in the California Medicaid Population. Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA and Department of Oral Medicine and Diagnostic Sciences, College of Dentistry and Cancer Center, College of Medicine, University of Illinois, Chicago, IL. PI: Dr. M. Nichol; Investigators: JD Epstein, JB Epstein. |
| 2006 – 2008 |
Risk and Outcomes Associated with Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung, and Ovarian Cancers,” Amgen. PI: Joel Epstein; Investigators: Joel Laudenbach, Dena Fischer, Gary Klasser, David Peace. |
| 2006 – 2007 |
A Randomized Trial Comparing Preservation of Function Status After Either Medpulser(R) Electroporation with Intratumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of Tongue, Posterior Lateral Pnaryngeal Wall, Hypopharynx or Larynx that Have Failed Primary Curative Therapy,” Genetronics. Principle Investigator: Mike Yao Co-Investigator: Joel Epstein. |
| 2024 – Ongoing |
Phase 1 Single Centre, open-labeled Clinical Trial to Evaluate the Safety and Tolerability of Topical Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis. SaNOtize Research and Development Corp. PI: Joel Epstein $40,005.00 |
